SCHEMBL6994754

SCHEMBL6994754

O=C(Nc1ccccc1O)c1ccsc1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
LMNA P02545 3/20 0.60
TP53 P04637 3/20 0.60
HTT P42858 3/20 0.60
GAA P10253 3/20 0.60
METAP2 P50579 1/20 0.53
RAB9A P51151 6/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
POLB P06746 1/20 0.50
STAT3 P40763 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 2/20 0.47
MAPT P10636 1/20 0.47
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
RPS6KA3 P51812 1/20 0.46
MAOB P27338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658768 0.80 KCNMA1 (0.54) NPC1LMNATP53GAARAB9A
SCHEMBL7664623 0.80 KCNMA1 (0.64) TP53GAAKMT2AMEN1POLB
SCHEMBL7666497 0.80 RAB9A (0.53) NPC1LMNAGAARAB9AKMT2A
SCHEMBL13292684 0.76 TDP1 (0.57) NPC1LMNATP53HTTRAB9A
SCHEMBL845142 0.76 LMNA (1.00) NPC1LMNATP53HTTGAA
SCHEMBL4930820 0.75 NPC1 (0.76) NPC1LMNATP53HTTGAA
SCHEMBL6997403 0.75 NPC1 (0.55) NPC1LMNATP53HTTGAA
SCHEMBL13292680 0.74 LMNA (0.39) LMNAHTTGAAKMT2AMAPT
SCHEMBL28842312 0.74 LMNA (0.96) NPC1LMNATP53HTTGAA
SCHEMBL28842439 0.74 LMNA (0.96) NPC1LMNATP53HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
CN-1268949-A Fused thiophene compounds and medical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2000-10-04 CN disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT NPC1 465/4885LMNA 4763/4885TP53 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.